US 12,268,726 B2
Treatment of rhinosinusitis with P-glycoprotein inhibitors
Benjamin S. Bleier, Weston, MA (US)
Assigned to Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed by Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed on Sep. 6, 2023, as Appl. No. 18/461,912.
Application 18/461,912 is a continuation of application No. 17/231,843, filed on Apr. 15, 2021, granted, now 11,786,574.
Application 17/231,843 is a continuation of application No. 16/725,213, filed on Dec. 23, 2019, granted, now 11,007,246, issued on May 18, 2021.
Application 16/725,213 is a continuation of application No. 15/687,074, filed on Aug. 25, 2017, granted, now 10,653,745, issued on May 19, 2020.
Application 15/687,074 is a continuation of application No. 14/655,662, granted, now 9,744,210, issued on Aug. 29, 2017, previously published as PCT/US2013/077945, filed on Dec. 27, 2013.
Claims priority of provisional application 61/746,290, filed on Dec. 27, 2012.
Prior Publication US 2024/0148823 A1, May 9, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/277 (2006.01); A61K 9/00 (2006.01); A61K 31/4164 (2006.01); A61K 31/43 (2006.01); A61K 31/4545 (2006.01); A61K 31/47 (2006.01); A61K 31/4725 (2006.01); A61K 31/473 (2006.01); A61K 31/496 (2006.01); A61K 31/545 (2006.01); A61K 31/55 (2006.01); A61K 31/56 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61K 31/65 (2006.01); A61K 31/7048 (2006.01); A61K 38/13 (2006.01); A61K 45/06 (2006.01); A61L 27/20 (2006.01); A61L 27/54 (2006.01)
CPC A61K 38/13 (2013.01) [A61K 9/0043 (2013.01); A61K 31/277 (2013.01); A61K 31/4164 (2013.01); A61K 31/43 (2013.01); A61K 31/4545 (2013.01); A61K 31/47 (2013.01); A61K 31/4725 (2013.01); A61K 31/473 (2013.01); A61K 31/496 (2013.01); A61K 31/545 (2013.01); A61K 31/55 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 31/65 (2013.01); A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61L 27/20 (2013.01); A61L 27/54 (2013.01)] 27 Claims
 
1. A method of treating chronic rhinosinusitis in a subject, the method comprising
identifying a subject having chronic rhinosinusitis; and
administering to the subject an effective amount of a P-glycoprotein inhibitor selected from the group consisting of PSC 833, R-verapamil, GF120918, VX-710, MS-209, LY335979, OC144093, R101933, XR9051, and XR9576.